uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

uniQure N.V.NASDAQ: QURE

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$36.06M, compared with -$23.51M a year earlier. Trailing-twelve-month EBITDA was -$129.14M.

Context

  • EBITDA amounted to 724.2% of revenue in FY2025, up 131.5 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of -$150.37M (-29.0%) for the fiscal year ending Dec 2026, a slowdown from the +27.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$36.06M-53.7% QoQ
Last fiscal yearDec 2025
-$116.59M+27.5% YoY
LTMMar 2026
-$129.14M+6.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.4%-111.4%-58.0 pp
1 year+27.5%-29.0%-56.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(116.59M) USD
Year-over-year change
+27.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 EBITDA of -$129.14M is the 4th highest of the 8 companies compared; the peer median is -$163.43M.
  • Its year-over-year change of +6.4% is the 3rd highest of 8, against a peer median of -11.9%.
  • EBITDA amounts to 713.8% of revenue for QURE, versus a peer median of 185.2%.
QURE Competitors Peer median
EBITDA for QURE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NGNENeurogene Inc.LTM Mar 2026-$95.45M -22.9%——
MGTXMeiraGTx Holdings plcLTM Mar 2026-$95.72M +32.5%—120.0%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$112.54M -37.5%—308.4%
QUREuniQure N.V.LTM Mar 2026-$129.14M +6.4%—713.8%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M +21.0%——
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M -11.9%—75.2%
Peer median (excluding QURE) -$163.43M-11.9%—185.2%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue524M106.48M15.84M27.12M16.1M
Cost of Revenue24.98M3.34M13.63M18.33M1.69M
Gross Profit499.03M103.14M2.22M8.79M14.41M
Gross Margin95.2%96.9%14.0%32.4%89.5%
Research & Development143.55M197.59M214.86M143.78M140.67M
Selling, General & Admin56.29M54.7M73.08M50.68M65.34M
Operating Expenses188.41M246.3M285.09M193.09M202.24M
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
EBITDA319M(108.02M)(253.1M)(160.75M)(116.59M)
EBITDA Margin60.9%-101.4%-1597.6%-592.7%-724.2%
Operating Income310.62M(143.16M)(282.87M)(184.29M)(187.83M)
Operating Margin59.3%-134.4%-1785.5%-679.6%-1166.8%
Interest Income162K609K19.56M21.42M16.97M
Interest Expense7.47M11.7M41.56M63.74M61.99M
Other Income / Expenses22.19M14.9M(23.69M)(52.83M)(5.51M)
Income Before Tax332.81M(128.26M)(306.56M)(237.13M)(193.34M)
Pre-Tax Margin63.5%-120.5%-1935.0%-874.4%-1201.0%
Income Tax Expense3.22M(1.47M)1.92M2.43M5.63M
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Net Margin62.9%-119.1%-1947.1%-883.4%-1236.0%
EPS (Basic)7.17(2.71)(6.47)(4.92)(3.46)
EPS (Diluted)7.04(2.71)(6.47)(4.92)(3.46)
Weighted Avg Shares45.99M46.74M47.67M48.65M57.5M
Weighted Avg Shares (Diluted)46.84M46.74M47.67M48.65M57.5M

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.